91.1 F
San Fernando
Thursday, Mar 28, 2024

Amgen Wins Otezla Patent Case

The U.S. District Court for New Jersey upheld patents that protect Otezla (apremilast), Amgen Inc.’s psoriasis treatment.

The Thousand Oaks pharma giant bought marketing right for Otezla two years ago for $13.4 billion. The patent infringement lawsuit against Sandoz Inc. and Zydus Pharmaceuticals Inc. prevents the two companies from making, using, selling, offering to sell or importing their versions of Otezla until February 2028, when the patent expires.

Sandoz and Zydus were found to have infringed on Amgen’s patents. The court upheld four patents, three against each of the two companies.

Otezla is approved in the U.S. for the treatment of adult patients with moderate-to-severe plaque psoriasis who are also candidates for photo or systemic therapy. It is also approved for adult patients with active psoriatic arthritis and adult patients with oral ulcers related to Behçet’s Disease.

The court ruled against Amgen on some claims concerning the dosing schedule methods for Otelza.

Shares of Amgen closed up 25 cents, or a fraction of a percent, to $215.36 on the Nasdaq Tuesday, a day when the market also closed up a fraction of a percent.

Antonio Pequeño IV
Antonio Pequeño IV
Antonio “Tony” Pequeño IV is a reporter covering health care, finance and law for the San Fernando Valley Business Journal. He specializes in reporting on some of the biggest names in the Valley’s biotechnology sector. In addition to his work with the Business Journal, Tony has reported with BuzzFeed News on the unsupervised use of Clearview AI, a controversial facial recognition technology. Tony, who also conducts freelance reporting, graduated from the USC’s Master of Science in Journalism program in 2021. He is in his fifth year as a journalist as of 2021.

Featured Articles

Related Articles